EVALUATION OF SERUM TOLL-LIKE RECEPTOR 4 AND NUCLEAR FACTOR-ÎšBP65 PROTEINS IN ORAL SQUAMOUS CELL CARCINOMA

Jayalalitha Sathiyamoorthy; Vidyarani Shyamsundar; N. Aravindha Babu; Subbaih Shanmugam; Jagadeesan. G. Mani; Ponnuraja Chinnaiyan; Rajeswary Hari

doi:10.22159/ajpcr.2018.v11i12.28234

Authors

Jayalalitha Sathiyamoorthy Department of Biotechnology, Dr. M.G.R. Educational and Research Institute, Chennai, Tamil Nadu, India.
Vidyarani Shyamsundar Department of Oral Pathology and Microbiology Centre of Oral Cancer Prevention and Research, Sree Balaji Dental College and Hospital, Bharath Institute of HigherEducation, Chennai, Tamil Nadu, India.
N. Aravindha Babu Department of Oral Pathology and Microbiology Centre of Oral Cancer Prevention and Research, Sree Balaji Dental College and Hospital, Bharath Institute of HigherEducation, Chennai, Tamil Nadu, India.
Subbaih Shanmugam Department of Surgical Oncology, Government Royapettah Hospital and Kilpauk Medical College, Chennai, Tamil Nadu, India.
Jagadeesan. G. Mani Department of Surgical Oncology, Government Royapettah Hospital and Kilpauk Medical College, Chennai, Tamil Nadu, India.
Ponnuraja Chinnaiyan Department of Statistics, National Institute of Research in Tuberculosis, Chennai, Tamil Nadu, India.
Rajeswary Hari Department of Biotechnology, Dr. M.G.R. Educational and Research Institute, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.28234

Keywords:

Oral squamous cell carcinoma, Oral epithelial dysplasia, Enzyme-linked immunosorbent assay, Toll-like receptor 4, Nil

Abstract

Objective: The present study is aimed to estimate the serum toll-like receptor 4 (sTLR 4) and nuclear factor-ÎºB (NF-ÎºB) p65 proteins in patients of oral squamous cell carcinoma (OSCC).

Methods: The study was performed in prospective cases of 22 OSCC patients, 10 oral epithelial dysplasia patients, 8 control with chewing habits, and 4 control patients. The estimation of sTLR 4 and NF-ÎºBp65 proteins was done by enzyme-linked immunosorbent assay method. The Pearson correlation test was performed to find out the relationship between these two proteins.

Results: There was an increase in the sTLR 4 protein level in study groups OSCC, oral premalignant disorders, control with chewing habits, and control habits such as 1.31 ng/mlÂ±1.06 ng/ml, 1.99 ng/mlÂ±0.98 ng/ml, and 2.11 ng/mlÂ±0.61 ng/ml, respectively, when comparable (p=0.008) to control patients with 0.60 ng/mlÂ±0.24 ng/ml. However, in the case of serum level NF-ÎºBp65 protein all the study groups including the control showed same values. The Pearson correlation test showed significant relationship (rpearson=0.91, [p<0.0005]) of these two proteins only in the OSCC patients.

Conclusion: It can be concluded that serum levels of TLR 4 are increased in OSCC patients, but there was no variation seen for the NF-ÎºBp65 protein. There is a strong interrelationship exist between the serum levels of TLR 4 and NF-ÎºBp65 proteins in the OSCC patients only.

Downloads

Download data is not yet available.

References

Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53:165-72.

Elango JK, Gangadharan P, Sumithra S, Kuriakose MA. Trends of head and neck cancers in urban and rural India. Asian Pac J Cancer Prev 2006;7:108-12.

Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J Dent Res 2008;87:14-32.

Misra S, Chaturvedi A, Misra NC. Management of gingivobuccal complex cancer. Ann R Coll Surg Engl 2008;90:546-53.

Howell RE, Wright BA, Dewar R. Trends in the oral cancer in Nova Scotia from 1983 to 1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:205-12.

Hasan S, Elongovan S. Conventional and advanced diagnostic aids in oral cancer screening â€“ The journey so far. Int J Pharm Pharm Sci 2014;7:29-33.

Sari LM, Subita GP, Auerkari EI. Potential antioxidant and cytotoxic activities of areca nut (Areca catechu linn.) extract in human oral squamous cell carcinoma and keratinocyte cells. Asian J Pharm Clin Res 2017;10:286-91.

Karin M. The Kappa kinase-a bridge between inflammation and cancer. Cell Res 2008;18:334-42.

Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28:4531-38.

Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011;12:715-23.

Zhu Z, Zhong S, Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 2011;12:95-105.

Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010;32:305-15.

Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.

Min R, Zun Z, Li S, Yang W, Lizheng W, Chenping Z. Increased expression of toll-like receptor 9 has close relation with tumor proliferation in oral squamous cell carcinoma. Arch Oral Biol 2011;56:877-84.

Bhattacharya D, Yusuf N. Expression of toll-like receptors on breast tumors: Taking a toll on tumor microenvironment. Int J Breast Cancer 2012;2012:716564-9.

Shen B, Dong P, Ying XJ. Expression of ABCG2 and NFkB p65 in nasopharyngeal cancer and its clinical significance. Chinese Clin Oncol 2012;17:424-7.

Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011;30:13-25.

Kelsh RM, McKeown-Longo PJ. Topographical changes in extracellular matrix: Activation of TLR4signaling and solid tumor progression. Trends Cancer Res 2013; 9:1-13.

Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: A double-edged sword for defines and offense. Arch Pharm Res 2012;35:1297-316.

Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L, et al. Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. Oncotarget 2016;7:40106-14.

Lan F, Yue X, Ren G, Wang Y, Xia T. Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC. Int J Clin Exp Pathol 2014;7:8087-95.

Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007,29:19-35.

Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-Îºb/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.

Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003.

Bell S, Degitz K, Quirling M, Jilg N, Page S, Brand K. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal 2003;15:1-7.

Oeckinghaus A, Ghosh S. The NF-ÎºB family of transcription factors and its regulation. Cold Spring Harbor Perspect Biol 2009;1:a000034.

Siggers T, Chang AB, Teixeira A, Wong D, Williams KJ, Ahmed B, et al. Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-ÎºB family DNA binding. Nat Immunol 2011;13:95-102.

Espinosa L, Ingles-Esteve J, Robert-Moreno A, Bigas A. IÎºBÎ± and p65 regulate the cytoplasmic shuttling of nuclear corepressors: Cross-talk between Notch and NFÎºB pathways. Mol Biol Cell 2003;14:491-502.

Wei H, Gao HQ, Li HB, Qi SJ, Liu WL, Xu L, et al. Correlation among RKIP expression, NFÎºB p65 levels, and T-lymphocyte subsets in gastric cardia adenocarcinoma. Genet Mol Res 2015;14:16491-6.